<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01376622</url>
  </required_header>
  <id_info>
    <org_study_id>CICL670AUS29T</org_study_id>
    <secondary_id>CCI-08-00143</secondary_id>
    <nct_id>NCT01376622</nct_id>
  </id_info>
  <brief_title>Changes in Pituitary Iron and Volume With Deferasirox</brief_title>
  <official_title>Changes in Pituitary Iron and Volume With Deferasirox in Transfusional Iron Overload</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite continuing advances in iron chelation therapy, iron toxicity of endocrine glands,
      particularly the pituitary gland, remains common in patients with transfusion dependent
      anemias. We would like to establish accurate population norms of pituitary R2 and volume and
      understand the progression of pituitary iron in transfused patients on Deferasirox.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">130</enrollment>
  <condition>Iron Overload</condition>
  <arm_group>
    <arm_group_label>Chronically Transfusion Patients</arm_group_label>
    <description>Patients with transfusion dependent anemia (excluding sickle cell disease), ages 2-25, on Deferasirox chelation therapy, to be monitored over 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Normal controls, ages 2-25, with no known brain abnormality or endocrine dysfunction.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Transfusion Dependent Anemia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Currently on chronic transfusion therapy.

          -  Duration of chronic transfusion &gt;1 year.

          -  Age 2 to 25 years

          -  On deferasirox monotherapy for the duration of the study.

          -  Informed consent from legal guardian and/or patient.

          -  On deferasirox for a minimum of 3 months at start of study.

        Exclusion Criteria:

          -  Sickle cell disease or sickle-beta zero genotype.

          -  Combination of deferasirox and another iron chelator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John C Wood, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wood JC, Noetzl L, Hyderi A, Joukar M, Coates T, Mittelman S. Predicting pituitary iron and endocrine dysfunction. Ann N Y Acad Sci. 2010 Aug;1202:123-8. doi: 10.1111/j.1749-6632.2010.05545.x.</citation>
    <PMID>20712782</PMID>
  </results_reference>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2011</study_first_submitted>
  <study_first_submitted_qc>June 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2011</study_first_posted>
  <last_update_submitted>June 17, 2011</last_update_submitted>
  <last_update_submitted_qc>June 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. John Wood</name_title>
    <organization>Children's Hospital Los Angeles</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron Overload</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferasirox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

